

Diabetes – Hypoglycemics – Incretin Mimetics/Enhancers ~~(18)~~

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD – Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS – Maximum Days’ Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have ‘X’ DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**

AmeriHealth Caritas Louisiana **1-800-684-5502**

Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**

Healthy Blue **1-844-521-6942**

Louisiana Healthcare Connections **1-888-929-3790**

UnitedHealthcare **1-800-310-6826**

Diabetes – Hypoglycemics – Incretin Mimetics/Enhancers (18)

POS Edits		
MD – Some agents are limited to a maximum dose as listed in the chart to the right.	Generic (Brand Example)	Maximum Dose
	Alogliptin (Nesina®, Generic)	25mg/day
	Alogliptin/Metformin (Kazano®, Generic)	25mg/2000mg per day
	Alogliptin/Pioglitazone (Oseni®, Generic)	25mg/45mg per day
	Dulaglutide (Trulicity®)	4.5mg/week
	Exenatide (Bydureon®, Bydureon® BCise™)	2mg/week
	Exenatide (Byetta®)	20mcg/day
	Linagliptin (Tradjenta®)	5mg/day
	Linagliptin/Metformin (Jentadueto®, Jentadueto XR®)	5mg/2000mg per day
	Liraglutide (Victoza®)	1.8mg/day
	Lixisenatide (Adlyxin®, Adlyxin® Starter Kit)	20mcg/day
	Pramlintide (Symlin®)	Type 1 diabetes: 60mcg SQ immediately prior to each major meal Type 2 diabetes: 120mcg SQ immediately prior to each major meal
	Saxagliptin (Onglyza®)	5mg/day
	Saxagliptin/Metformin ER (Kombiglyze XR®)	5mg/2000mg per day
	Semaglutide (Ozempic®)	1mg/week
Sitagliptin (Januvia®)	100mg/day	
Sitagliptin/Metformin (Janumet®, Janumet XR®)	100mg/2000mg per day	
QL – Some agents are limited to a maximum quantity based on a 30-day supply as listed in the chart to the right.	Generic (Brand Example)	Quantity Limit per 30 days
	Dulaglutide (Trulicity®)	1 syringe per week Dulaglutide (Trulicity®)
	Empagliflozin/Linagliptin/Metformin (Trijardy® XR) 5 mg / 2.5 mg / 1000 mg	60 tablets <u>per 30 days</u>
	Empagliflozin/Linagliptin/Metformin (Trijardy® XR) 10 mg / 5 mg / 1000 mg	30 tablets <u>per 30 days</u>
	Empagliflozin/Linagliptin/Metformin (Trijardy® XR) 12.5 mg / 2.5 mg / 1000 mg	60 tablets <u>per 30 days</u>
	Empagliflozin/Linagliptin/Metformin (Trijardy® XR) 25 mg / 5 mg / 1000 mg	30 tablets <u>per 30 days</u>

POS Edits		
	Semaglutide (Rybelsus®)	30 tablets <u>per 30 days</u>
TD	<ul style="list-style-type: none"> • GLP-1 receptor agonists are monitored at the pharmacy POS for duplication of therapy with DPP-4 inhibitors. Conversely, DPP-4 inhibitors are monitored at the pharmacy POS for duplication of therapy with GLP-1 receptor agonists. • Empagliflozin/Linagliptin/Metformin (Trijardy® XR) is monitored at the pharmacy POS for duplication of therapy with DPP-4 inhibitors. Conversely, DPP-4 inhibitors are monitored at the pharmacy POS for duplication of therapy with empagliflozin/linagliptin/metformin (Trijardy® XR). • Empagliflozin/Linagliptin/Metformin (Trijardy® XR) is monitored at the pharmacy POS for duplication of therapy with SGLT2s. Conversely, SGLT2s are monitored at the pharmacy POS for duplication of therapy with empagliflozin/linagliptin/metformin (Trijardy® XR). 	
PU	<ul style="list-style-type: none"> • For empagliflozin/linagliptin/metformin (Trijardy® XR), the pharmacy POS system verifies that there has been one of the following: <ul style="list-style-type: none"> ○ at least a 90-day supply of ONE of the following in the previous 180-day period: <ul style="list-style-type: none"> ▪ metformin AND either a DPP-4 or an SGLT2; OR ▪ a combination DPP-4/metformin or SGLT2/metformin; OR ○ at least a 60-day supply of empagliflozin/linagliptin/metformin (Trijardy® XR) in the previous 90-day period. • For all other agents, the pharmacy POS system verifies that there has been one of the following: <ul style="list-style-type: none"> ○ at least a 90-day supply of metformin in the previous 180-day period; OR ○ at least a 60-day supply of any incretin mimetic/enhancer in the previous 90-day period. 	

<u>Revision / Date</u>	<u>Implementation Date</u>
Created POS Document / February 2020	February 2020
Added therapeutic duplication information Rybelsus® quantity limit / July 2020	July-August 2020
Added POS edits for Trijardy XR / July 2020	July 2020 October 2020
Updated age for BH in POS Abbreviations chart / November 2020	November 2020 January 2021
Increased maximum dose of Trulicity® / April 2021	April 2021
Changed maximum dose to quantity limit for Trulicity® / April 2021	April 2021 July 2021

